Recent Updates
Recently added Catalysts
TFX Positive Sentiment

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

Tuesday, September 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Teleflex Incorporated announced a peer-reviewed study published in the American Journal of Infection Control. The study found that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology significantly reduced the risk of central line-associated bloodstream infections (CLABSIs) by 70% compared to standard catheters. This finding highlights the effectiveness of the technology in improving patient safety.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant reduction in CLABSI risk demonstrated.
  • Study published in a reputable journal.
  • Arrowg+ard™ Technology shows strong efficacy.

Full Press Release Details

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a 30

Frequently Asked Questions

What does Arrowg+ard™ Technology do?

Arrowg+ard™ Technology is designed to reduce the risk of central line-associated bloodstream infections.

How much does Arrowg+ard™ Technology reduce CLABSI risk?

The technology is associated with a statistically significant 70% lower hazard of CLABSIs.

Where was the study on Arrowg+ard™ Technology published?

The study was published in the American Journal of Infection Control.

What type of catheters were compared in the study?

The study compared Central Venous Catheters protected with Arrowg+ard™ Technology to plain, non-impregnated catheters.

ShareAdd on Google
Tags: TFX Teleflex Arrowg+ard CLABSI CVCs medical technology
Last updated: Sep 29, 2026

Biotech snapshot

Cash runway
$327M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Arterial SealingPhase 3
Hemostasis of Arterial Punctures →